SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

The revenue for the December 2022 quarter is pegged at Rs. 7991.10 millions against Rs. 8079.80 millions recorded during the year-ago period.A slim rise of 19.24% was recorded in the Net profit for the quarter ended December 2022 to Rs. 1640.30  millions  From Rs. 1375.60 millions.The company reported a good operating profit of 2514.00 millions compared to 2071.60 millions of corresponding previous quarter.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202212 202112 % Var 202212 202112 % Var 202203 202103 % Var
Sales 7991.10 8079.80 -1.10 24341.80 24255.90 0.35 32175.10 29204.70 10.17
Other Income 236.00 105.00 124.76 735.50 572.80 28.40 762.20 1101.90 -30.83
PBIDT 2514.00 2071.60 21.36 7062.00 6396.80 10.40 8320.50 7079.60 17.53
Interest 0.90 5.80 -84.48 11.60 17.20 -32.56 19.90 35.30 -43.63
PBDT 2399.40 1886.60 27.18 6936.70 6200.40 11.88 8416.40 5318.30 58.25
Depreciation 164.10 178.70 -8.17 485.90 528.40 -8.04 681.90 786.00 -13.24
PBT 2235.30 1707.90 30.88 6450.80 5672.00 13.73 7734.50 4532.30 70.65
TAX 595.00 332.30 79.06 1718.60 1354.80 26.85 3968.70 1665.40 138.30
Deferred Tax -95.10 -57.10 66.55 -176.10 -129.70 35.77 -105.00 78.70 -233.42
PAT 1640.30 1375.60 19.24 4732.20 4317.20 9.61 3765.80 2866.90 31.35
Equity 1694.10 1694.10 0.00 1694.10 1694.10 0.00 1694.10 1694.10 0.00
PBIDTM(%) 31.46 25.64 22.70 29.01 26.37 10.01 25.86 24.24 6.68

Glaxosmithkline Phar Share Price

2451.80 32.70 (1.35%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×